UA110293C2 - Macrocyclic derivatives for the treatment of proliferative diseases - Google Patents

Macrocyclic derivatives for the treatment of proliferative diseases

Info

Publication number
UA110293C2
UA110293C2 UAA201408703A UAA201408703A UA110293C2 UA 110293 C2 UA110293 C2 UA 110293C2 UA A201408703 A UAA201408703 A UA A201408703A UA A201408703 A UAA201408703 A UA A201408703A UA 110293 C2 UA110293 C2 UA 110293C2
Authority
UA
Ukraine
Prior art keywords
treatment
proliferative diseases
salts
alk
compounds
Prior art date
Application number
UAA201408703A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Simon Bailey
Benjamin Joseph Burke
Michael Raymond Collins
Jingrong Jean Cui
Judith Gail Deal
Robert Louis Hoffman
Qinhua Huang
Ted William Johnson
Robert Steven Kania
John Charles Kath
Phuong Thi Quy Le
Michele Ann Mctigue
Cynthia Louise Pflmer
Paul Francis Richardson
Neal William Sach
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority claimed from PCT/IB2013/051391 external-priority patent/WO2013132376A1/en
Publication of UA110293C2 publication Critical patent/UA110293C2/en

Links

Abstract

Винахід стосується сполуки формули (Ф):,як далі визначено в даному документі, та її фармацевтично прийнятних солей, фармацевтичних композицій, що містять такі сполуки та солі, та їх застосувань.Сполуки та солі за представленим винаходом інгібують кіназу анапластичної лімфоми (ALK) та/або EML4-ALK та є корисними для лікування розладів або покращення стану при розладах, пов'язаних з аномальною клітинною проліферацією, таких як рак.The invention relates to a compound of formula (F): as hereinafter defined, and its pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds and salts, and their uses. The compounds and salts of the present invention inhibit anaplastic lymphoma (ALK) kinase and / or EML4-ALK and are useful for treating disorders or improving their condition for abnormal cell proliferation disorders such as cancer.

UAA201408703A 2012-03-06 2013-02-20 Macrocyclic derivatives for the treatment of proliferative diseases UA110293C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607485P 2012-03-06 2012-03-06
PCT/IB2013/051391 WO2013132376A1 (en) 2012-03-06 2013-02-20 Macrocyclic derivatives for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
UA110293C2 true UA110293C2 (en) 2015-12-10

Family

ID=55171500

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201408703A UA110293C2 (en) 2012-03-06 2013-02-20 Macrocyclic derivatives for the treatment of proliferative diseases

Country Status (2)

Country Link
MA (1) MA37291B1 (en)
UA (1) UA110293C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112321604A (en) * 2019-08-05 2021-02-05 华东理工大学 Macrocyclic JAK2 inhibitor and application thereof

Also Published As

Publication number Publication date
MA37291A3 (en) 2018-05-31
MA37291A2 (en) 2016-10-31
MA37291B1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
PH12014501992A1 (en) Macrocyclic derivatives for the treatment of proliferative diseases
AU2011297889A8 (en) Pharmaceutically active compounds as Axl inhibitors
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
MX352672B (en) Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer.
MX361815B (en) Pyrazolopyrimidine compounds as kinase inhibitors.
NZ708864A (en) Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
EP4275756A3 (en) Bipyrazole derivatives as jak inhibitors
MX2015012427A (en) Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer.
EA201201161A1 (en) PYRROPYRIMIDINES AS CDK4 / 6 INHIBITORS
MX2011011335A (en) Inhibitors of pi3 kinase and / or mtor.
MX2013012776A (en) Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors.
EA201590879A1 (en) ARYL-CONDENSED AND HETEROARYL-CONDENSED LACTAMS
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX2013001361A (en) 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors.
JO3115B1 (en) Pyridazinone Compounds and Their Use as DAAO Inhibitors
MX340300B (en) Chromenone compounds as pi 3 -kinase inhibitors for the treatment of cancer.
MX2014000964A (en) Substituted heterocyclic aza derivatives.
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
PH12014502547A1 (en) Dosage regimen for a pi-3 kinase inhibitor
IN2015DN01408A (en)
MX362896B (en) Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer.
MX2015012600A (en) Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl) methanone compounds as cancer cell growth inhibitors.
UA110293C2 (en) Macrocyclic derivatives for the treatment of proliferative diseases
CU20140107A7 (en) MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES
EA201600411A1 (en) DERIVATIVES OF PIPERIDINE FOR APPLICATION IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS